poisar

Stocks · News reference

GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBVGMAB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Sns Insider

    Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider

    The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

    BMRNPFEABBVSNYTAK
  3. Reuters Events

    Reuters Momentum AI Austin Day 1: A New Way to Measure Whether AI Is Actually Paying Off

    Enterprise AI is shifting from experimentation to demonstrating measurable ROI. Companies like FedEx ($3B in cost reductions), Mars (20% top-line growth), and Indeed (70% of matches from AI) are scaling AI beyond pilots, but success requires organizational redesign, clear ownership, and human oversight. Leaders warn that AI can amplify existing organizational weaknesses and autonomous agents need defined spending limits and accountability measures.

    FDXABBVWBDUNHSCHW
  4. Na

    ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

    ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing siRNA therapeutics, priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026. AbbVie has agreed to purchase shares in a concurrent private placement for approximately $100 million, resulting in a 4.9% stake in ADARx.

    ABBV
  5. Na

    Grant of Restricted Stock Units and Warrants to Employees in Genmab

    Genmab A/S announced the grant of 13,794 restricted stock units and 13,331 warrants to employees. The RSUs have a fair value of DKK 2,268 per unit and will vest after three years, while warrants have an exercise price of DKK 2,268 with a Black-Scholes fair value of DKK 781.96, vesting in three years and expiring after seven years.

    GMAB